Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review
Autor: | Burkhard Pieper, Mourad Farouk Rezk |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
Adult
Male 030213 general clinical medicine medicine.medical_specialty Disease Review Anti-TNF 03 medical and health sciences 0302 clinical medicine Rheumatology Early treatment medicine Humans Pharmacology (medical) Intensive care medicine Biosimilar Pharmaceuticals Disease burden Aged Aged 80 and over Inflammation Biosimilars Modalities business.industry Tumor Necrosis Factor-alpha Biologic therapies Correction Biosimilar General Medicine Middle Aged Access to treatment medicine.disease Europe Treatment Outcome Immune System Diseases 030220 oncology & carcinogenesis Patient outcomes Chronic Disease Immune-mediated inflammatory diseases Narrative review Female Maintenance of remission business IMIDs Healthcare system |
Zdroj: | Advances in Therapy |
ISSN: | 1865-8652 0741-238X |
Popis: | Immune-mediated inflammatory diseases (IMIDs) are chronic conditions that create a significant disease burden on millions of patients while adding a major financial burden to societies and healthcare systems. The introduction of biologic medicines has contributed majorly to improving the clinical outcomes of IMIDs and as such these modalities have gained first- or second-line positions in a wide range of treatment guidelines from different international clinical societies. However, the high cost of these biologics traditionally limited their accessibility and delayed their initiation, leaving millions of patients with unmet medical needs for a more affordable and sustainable solution. The introduction of cost-efficient biosimilar anti-TNFs within Europe since 2013 has allowed more patients with IMIDs to access biologic therapies earlier and for longer, potentially altering the course of the disease into a milder phenotype and reducing the long-term disease burden. This review provides the latest evidence for the impact of biosimilars on patient outcomes and demonstrates their clinical value beyond a reduction in price. |
Databáze: | OpenAIRE |
Externí odkaz: |